Glucagon-like peptide-1 agonist

From Wikipedia, the free encyclopedia

Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes.[1] Known as the "incretin mimetics".

One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]

There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas [3]

Licensed GLP-1 agonists:

Under investigation: [1]

References

  1. ↑ 1.0 1.1 Baggio et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". 
  2. ↑ American Diabetes Association (2011). "Standards of Medical Care in Diabetes--2012". Diabetes Care 35: S11–S63. doi:10.2337/dc12-s011. PMID 22187469. 
  3. ↑ http://www.bmj.com/content/346/bmj.f2743
  4. ↑ "FDA Approves New Treatment for Type 2 Diabetes". 
Oral anti-diabetic drugs and Insulin analogs (A10)
Insulin
Sensitizers
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Secretagogues
Meglitinides/"glinides"
  • Fasiglifam†
Analogs/other insulins
Other
Amylin analog
SGLT2 inhibitors
Other

M: END

anat/phys/devp/horm

noco (d)/cong/tumr, sysi/epon

proc, drug (A10/H1/H2/H3/H5)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.